PFE (Pfizer, Inc.)

PFE (Pfizer, Inc.)

• Entry Price: $16.07
• Risk Level:8
• Profitability Level: 7
• 1year Target Price: $20-$25

Having settled the 1996 Trovan clinical study case with the Kano State government in Nigeria, Pfizer can move forward to other developing drugs. Pfizer Inc (NYSE: PFE), together with Medivation, Inc. (NASDAQ: MDVN) has started the initiation of a Phase 3 trial of the investigational drug Dimebon (Latrepirdine) in patients with Huntington disease. In addition, the U.S. Food and Drug Administration (FDA) have granted orphan drug designation to Dimebon for the treatment of Huntington disease.

On January 26, 2009 Pfizer and Wyeth entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction. The conglomerate company will create one of the most diversified companies in the global health care industry, with product offerings in numerous growing therapeutic areas, a strong product pipeline, and leading scientific and manufacturing capabilities.

Yahoo analysts estimate growth for the following year to be 13.8%; 3.8% over the industry’s projected growth, making Pfizer a hot stock to buy.

We wish you luck on your investments and as always do your own research prior to purchasing or selling a stock. We make recommendations based on our own research and this site is solely for the purpose of entertainment reading. Thank you for visiting Hot Stocks to Buy.

MRK - MERCK, Inc.

MRK (MERCK, Inc)

• Entry Price: $30.02
• Risk Level: 8
• Profitability Level: 7
• 1year Target Price: $35-$40

Despite all the legal troubles surrounding Merck’s Vioxx drug, the company is still going strong with other marketable drugs. On July 31, 2009 the U.S. Food and Drug Administration (FDA) approved and expanded the use for ISENTRESS®. ISENTRESS can now be used in the treatment of adult patients starting HIV-1 therapy for the first time (treatment-naïve), as well as in treatment-experienced adult patients. ISENTRESS is used in combination with other antiretroviral (ARV) medicines for the treatment of HIV-1 infection in adult patients.

With the announcement of Merck & Co.’s head of vaccine retirement effective Nov. 1 2009, this could be beneficial to the company considering it has been plagued by management decisions that lead to manufacturing deficiencies cited by the Food and Drug Administration which reduced sales significantly. During March 2009 Merck unanimously approved a $41.1 billion acquisition of partner drug maker Schering-Plough Corp. of Kenilworth, N.J. This merger will lead to cost-cutting and give Merck a better edge over the drug industry.

With a cost-cutting merger on the way and reorganization at the management level to come, analysts at Yahoo Finance still estimate a profit margin of 24.59% and 5.0% earnings for the next year making Merck hot stock to buy with a mid to high level of risks.

We wish you luck on your investments and as always do your own research prior to purchasing or selling a stock. We make recommendations based on our own research and this site is solely for the purpose of entertainment reading. Thank you for visiting Hot Stocks to Buy.

HGSI - Human Genome Sciences, Inc.

HGSI (Human Genome Sciences, Inc.)

• Entry price: $14
• Risk Level:  9
• Profit Potential: 9
• 1 yr Target Price: $25-$35

According to Yahoo Finance, Analysts estimate a 93.9% growth this year.

With substantial financial rights to certain products in GlaxoSmithKline, Amgen, Genentech and Roche’s line of drugs, all are major players in the clinical drug industry; HGS is a hot stock to buy.  Some of these drugs include darapladib(in Phase III development as a treatment for coronary heart disease) and Syncria (albiglutide)(in Phase III development as a treatment for type 2 diabetes).  Both of these drugs are promising and have high potential to send stock prices up.

Furthermore, HGS has a strategic agreement with Novartis International Pharmaceutical, Ltd. for the co-development and commercialization of ZALBIN™ (formerly Albuferon®) which has completed Phase 3 development in chronic hepatitis C.  They are expecting to submit global marketing applications in fall 2009.

Another promising drug in the late stages of development is BENLYSTA™ (formerly LymphoStat-B®).  HGS successfully completed the initial Phase 3 trial treatment of systemic lupus and results of the second BENLYSTA Phase 3 trial are also expected in November 2009.

In the first half of 2009, HGS achieved its first product revenues of $162.7 million when they delivered raxibacumab (ABthrax(TM)) to the U.S. Strategic National Stockpile for the treatment of inhalation anthrax. In July 2009, HGS also secured a new purchase order for 45,000 doses of raxibacumab to be delivered to the U.S. Strategic National Stockpile over a three-year period.

Having one already commercialized drug, two in the process to be commercialized in fall 2009 and 2 high potential drugs in development make HGS a great short term buy.

We wish you luck on your investments and as always do your own research prior to purchasing or selling a stock. We make recommendations based on our own research and this site is solely for the purpose of entertainment reading. Thank you for visiting Hot Stocks to Buy.

AVII - Upgraded to Super Hot Buy

[AVII] AVI Biopharma, Inc. - Hot Stocks to Buy Entry Price $0.99

• Risk Level : 10
• Profit Potential: 8
• Price Target 6 months: $2.75 - $3
• Price Target 12 months: $3.5 - $3.75

We originally added AVII to our Hot Stocks to Buy list on April 28th during the start of the Mexican Swine Flu outbreak.  On April 28th, AVII was trading at .99 cents, which was low compared to their competitors.  They were basically lagging behind the other Flu related stocks.  Since April 28th, AVII has jumped more than 50% to over $1.50 per share.

We are upgrading AVII  to a Super Hot Buy stock for a couple of reasons.

• Swine flu has not gone away and is actually growing in cases.  We expect increased chatter in the coming summer months.
• Experts are expecting this year’s flu season to be worst than typical years.

AVII should do well in the current stock market environment as they are typically resistent to the Economy’s woes.

We wish you luck on your investments and as always do your own research prior to purchasing or selling a stock. We make recommendations based on our own research and this site is solely for the purpose of entertainment reading. Thank you for visiting Hot Stocks to Buy.

“June Gloom” Sets In

After a stellar start to June, the stock market gives up almost all of it’s June gains in two trading days. Yesterday’s loss of 188 points plus today’s negative 107 points takes the Dow back to just a couple of points from where it started June at. This sharp sell off may be a sign of things to come as the market absorbed today’s good housing startup data and continued to fall further. This looks very similar to the trend in May when bad news was absorbed and the market continue to rise; something like a “bizarro” effect. The rapid decline in the last 15 minutes of trading does not bold well for Wednesday. With options expirations coming this Friday (Quadruple Witching), this could be the beginning of a shorterm selloff as many families prepare for Summer break.

S - Sprint Nextel Corp.

[S] Sprint Nextel Corp. - Hot Stocks to Buy Entry Price $5 - $5.50

• Risk level: 5
• Profit potential: 7
• Price Target 6 months: $7 - $8
• Price Target 12 months: $10 - $12
• We expect Sprint to outperform the market in the short and long term.

Today we are selecting Sprint Nextel Corp. (S) as a hot stocks to buy. Since bottoming out on November 20th, 2008 at the price of $1.37 per share, Sprint has more than quadrupled in price to $5 per share. The share price has somewhat been stagnant the past month and a half as share holders await the recently released Palm Pre. The debut of the Palm Pre on June 8th has to be considered successful as it is expected to sell over 50,000 units in it’s first day of release. For the quarter, Palm expects to sell over450,000 units.  This is good news for Sprint as roughly 80-90% of all Palm Pre customers are expected to use Sprint’s service.

The additional customers gained from the Palm Pre release should add to the bottom line for Sprint when they report in the third quarter later this year. We see Sprint as a well established company that took a big punch in November of 08 and withstood it. Sprint is still in it’s early stage of recovery and with some bumps along the way, we expect the stock to eventually get above $12 per share over the next 12 months.

We wish you luck on your investments and as always do your own research prior to purchasing or selling a stock. We make recommendations based on our own research and this site is solely for the purpose of entertainment reading. Thank you for visiting Hot Stocks to Buy.

Welcome to June in a Big Way!

Wow June started out great as the Dow surged 241 points and NASDAQ added 62 points during the first two trading days of the month. On Monday and Tuesday stocks were bolstered by good economic data and the conclusion of the General Motors faith.

Today, the stock market has given back close to half of the gains from Monday and Tuesday as the Dow is down 100 and the NASDAQ is down over 30 points. Most of the decline can be attributed to worst than expected economic data. The Commerce Department said that factory order rose 0.7 percent, missing the widely expected number of 0.9. Also the service industry showed an eighth consecutive monthly decline.

Today’s decline can be seen as a welcomed break from the hot 4 session rally. We expect to see the stock market cool down a little from their recent gains. June is typically a poor month for stocks but this year has been far from typical so we will keep a close watch. The direction of the market can quickly shift as more government intervention is expected in the near future. We expect June to be a very rocky month for stocks.

Consumer Confidence Rally? What a Joke!

It’s such a joke to see the rally on Monday, based solely on a consumer confidence report. Needless to say, this joke will be discovered very soon and the gains will be given back shortly. We continue to remain bearish on the stock market, our advice is to take profit from Monday’s rally and watch the market retract the rest of the week. The hot air balloon is primed to bust in the short term.

No Hot Stocks to Buy!

We tried and tried and then tried again, but there’s just no hot stocks that we’d like to recommend at this time. We still like GERN and the sector that they are in but besides that there’s not much on our radar. Last week the stock market had a quick and unexpected rise on Monday. On our Tuesday night blog, we mentioned to our subscribers that we expected the stock market to give back all the gains made on Monday by the end of the week. We were off by 9 points on the Dow and 12 points on the NASDAQ.

This coming week after Memorial Day weekend, we expect the stock market to continue on it’s downward trend. Some important economic news expected this week are as follows:

• 26-May S&P/CaseShiller Home Price Index
• 26-May Consumer Confidence
• 27-May Existing Home Sales
• 28-May New Home Sales

Keep an eye on these reports as they can lead the market higher or lower, depending on how the results are perceived.


As we celebrate Memorial Day, we thank all the troops over seas for courageously protecting our country. We wish them and their families a warm Memorial Day.

Stock Market Correction Over?

After Monday’s 235 point increase on the Dow Jones, many would consider the notion that the recent correction that started on May 11th is over. Well that’s a little too optimistic for us. The impressive gains on Monday was a bit unexpected, in our opinion, we can expect the market to give back the gains later this week. Eventually the stock market will not be able to ignore all the negative economic news. As we have been preaching the last two weeks, the stock market is overbought and will retract. Below are some reasoning behind our opinion.

• Job losses have continued to increase
• Consumer spending is down and Hewlett Packard’s recent report of a 17 percent profit drop, 3 percent sales drop, and to top it off, a 2 percent job layoff
• The housing start numbers are at their lowest since 1956, signs that we are still in the heart of a recession
• Oil prices starting to creep past $60 a barrel

With so many reasons to sell, its an anomaly as to why the market is still up.  We continue our bearish outlook in the overall market.


As always we wish you luck on your investments and as always do your own research prior to purchasing or selling a stock. We make recommendations based on our own research and this site is solely for the purpose of entertainment reading. Thank you for visiting Hot Stocks to Buy

« Previous Page — Next Page »